With Nycomed, Takeda Satifies Both Strategic And Financial Objectives
By
Melanie Senior / Email the Author / IN VIVO June 2011, Vol. 29, No. 6
Around The Industry / Word Count: 1473 / Article # 2011800101
Executive Summary
Takeda Pharmaceutical Co.'s $13.7 billion purchase of privately held Nycomed International Management is undoubtedly pricey, at over three times the Swiss group's 2010 revenues. But because it satisfies a number of strategic and financial imperatives, the deal - Takeda's largest ever - may be worth the cost.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.